{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:38:49Z","timestamp":1787755129293,"version":"build-2784847793"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S GmbH","award":["125346"],"award-info":[{"award-number":["125346"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>European trials using procalcitonin (PCT)-guided antibiotic therapy for patients with lower respiratory tract infections (LRTIs) have demonstrated significant reductions in antibiotic use without increasing adverse outcomes. Few studies have examined PCT for LRTIs in the United States.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this study, we evaluated whether a PCT algorithm would reduce antibiotic exposure in patients with LRTI in a US hospital. We conducted a controlled pre-post trial comparing an intervention group of PCT-guided antibiotic therapy to a control group of usual care. Consecutive patients admitted to medicine services and receiving antibiotics for LRTI were enrolled in the intervention. Providers were encouraged to discontinue antibiotics according to a PCT algorithm. Control patients were similar patients admitted before the intervention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The primary endpoint was median antibiotic duration. Overall adverse outcomes at 30 days comprised death, transfer to an intensive care unit, antibiotic side effects, Clostridium difficile infection, disease-specific complications, and post-discharge antibiotic prescription for LRTI. One hundred seventy-four intervention patients and 200 controls were enrolled. Providers complied with the PCT algorithm in 75% of encounters. Procalcitonin-guided therapy reduced median antibiotic duration for pneumonia from 7 days to 6 (P = .045) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) from 4 days to 3 (P = .01). There was no difference in the rate of adverse outcomes in the PCT and control groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A PCT-guided algorithm safely reduced the duration of antibiotics for treating LRTI. Utilization of a PCT algorithm may aid antibiotic stewardship efforts.<\/jats:p>\n                  <jats:p>This clinical trial was a single-center, controlled, pre-post study of PCT-guided antibiotic therapy for LRTI. The intervention (incorporation of PCT-guided algorithms) started on April 1, 2017: the preintervention (control group) comprised patients admitted from November 1, 2016 to April 16, 2017, and the postintervention group comprised patients admitted from April 17, 2017 to November 29, 2017 (Supplementary Figure 1). The study comprised patients admitted to the internal medicine services to a medical ward, the Medical Intensive Care Unit (MICU), the Cardiac Intensive Care Unit (CICU), or the Progressive Care Unit (PCU) \u201cstep down unit\u201d. The registration data for the trails are in the ClinicalTrials.gov database, number NCT0310910.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofy327","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T12:39:55Z","timestamp":1543840795000},"source":"Crossref","is-referenced-by-count":30,"title":["Procalcitonin-Guided Antibiotic Therapy Reduces Antibiotic Use for Lower Respiratory Tract Infections in a United States Medical Center: Results of a Clinical Trial"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-3493","authenticated-orcid":false,"given":"Jennifer","family":"Townsend","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagis","family":"Galiatsatos","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pearse","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardin","family":"Pantle","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Masterson","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Kisuule","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsen","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kiruthi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Agbanlog","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jurao","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Stern","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Nayak","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Melgar","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Sama","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Irwin","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Mazidi","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Psoter","sequence":"additional","affiliation":[{"name":"Division of General Pediatrics and Adolescent Medicine, School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"McKenzie","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"2020081004290819300_CIT0001","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Prevalence of antimicrobial use in US acute care hospitals, May-September 2011","volume":"312","author":"Magill","year":"2014","journal-title":"JAMA"},{"key":"2020081004290819300_CIT0002","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archinte.163.8.972","article-title":"Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity","volume":"163","author":"Hecker","year":"2003","journal-title":"Arch Intern Med"},{"key":"2020081004290819300_CIT0003","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s11606-017-4099-6","article-title":"Categorical risk perception drives variability in antibiotic prescribing in the emergency department: a mixed methods observational study","volume":"32","author":"Klein","year":"2017","journal-title":"J Gen Intern Med"},{"key":"2020081004290819300_CIT0004","article-title":"Influencing antibiotic prescribing behavior: inpatient settings.","volume-title":"Presidential Advisory Council on Combating Antibiotic Resistance","author":"Szymczak","year":"2017"},{"key":"2020081004290819300_CIT0005","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201501-0017OC","article-title":"Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia","volume":"192","author":"Claessens","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2020081004290819300_CIT0006","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.201507-1460ED","article-title":"The diagnosis of community-acquired pneumonia. Do we need to take a big step backward?","volume":"192","author":"Waterer","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2020081004290819300_CIT0007","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0140-6736(93)90277-N","article-title":"High serum procalcitonin concentrations in patients with sepsis and infection","volume":"341","author":"Assicot","year":"1993","journal-title":"Lancet"},{"key":"2020081004290819300_CIT0008","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1210\/jc.2002-021444","article-title":"Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors","volume":"89","author":"Becker","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020081004290819300_CIT0009","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial","volume":"375","author":"Bouadma","year":"2010","journal-title":"Lancet"},{"key":"2020081004290819300_CIT0010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(83)91704-X","article-title":"Hypercalcitoninaemia in fulminant meningococcaemia in children","volume":"1","author":"Mallet","year":"1983","journal-title":"Lancet"},{"key":"2020081004290819300_CIT0011","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.2009.1297","article-title":"Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial","volume":"302","author":"Schuetz","year":"2009","journal-title":"JAMA"},{"key":"2020081004290819300_CIT0012","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/CCM.0B013E318165BABB","article-title":"Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations","volume":"36","author":"Becker","year":"2008","journal-title":"Crit Care Med"},{"key":"2020081004290819300_CIT0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-8981(02)00101-8","article-title":"Pathobiochemistry and clinical use of procalcitonin","volume":"323","author":"Meisner","year":"2002","journal-title":"Clin Chim Acta"},{"key":"2020081004290819300_CIT0014","article-title":"Antibiotic guidelines: treatment recommendations for adult inpatients","author":"Cosgrove","year":"2015","journal-title":"Johns Hopkins Medicine"},{"key":"2020081004290819300_CIT0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/thorax.58.5.377","article-title":"Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study","volume":"58","author":"Lim","year":"2003","journal-title":"Thorax"},{"key":"2020081004290819300_CIT0016","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.arbres.2017.02.001","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary","volume":"53","author":"Vogelmeier","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"2020081004290819300_CIT0017","volume-title":"Sabatani N. Inpatient (Discharge) Dataset"},{"key":"2020081004290819300_CIT0018","volume-title":"Antimicrobial Use and Resistance (AUR) Module","author":"NHSN","year":"2015"},{"key":"2020081004290819300_CIT0019","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0140-6736(04)15591-8","article-title":"Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial","volume":"363","author":"Christ-Crain","year":"2004","journal-title":"Lancet"},{"key":"2020081004290819300_CIT0020","first-page":"CD007498","article-title":"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections","volume":"10","author":"Schuetz","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2020081004290819300_CIT0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12873-017-0138-1","article-title":"Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection","volume":"17","author":"Huang","year":"2017","journal-title":"BMC Emerg Med"},{"key":"2020081004290819300_CIT0022","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.2012.19","article-title":"Physician autonomy and health care reform","volume":"307","author":"Emanuel","year":"2012","journal-title":"JAMA"},{"key":"2020081004290819300_CIT0023","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1802670","article-title":"Procalcitonin-guided use of antibiotics for lower respiratory tract infection","volume":"379","author":"Huang","year":"2018","journal-title":"N Engl J Med"},{"key":"2020081004290819300_CIT0024","doi-asserted-by":"crossref","first-page":"ofx213","DOI":"10.1093\/ofid\/ofx213","article-title":"Impact of procalcitonin-guided antibiotic management on antibiotic exposure and outcomes: real-world evidence","volume":"4","author":"Broyles","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020081004290819300_CIT0025","volume-title":"New Antimicrobial Stewardship Standard MM.09.01.01","author":"The Joint Commission","year":"2017"},{"key":"2020081004290819300_CIT0026","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/infdis\/jiv252","article-title":"Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial","volume":"212","author":"Branche","year":"2015","journal-title":"J Infect Dis"},{"key":"2020081004290819300_CIT0027","doi-asserted-by":"crossref","first-page":"e0152986","DOI":"10.1371\/journal.pone.0152986","article-title":"Provider decisions to treat respiratory illnesses with antibiotics: insights from a randomized controlled trial","volume":"11","author":"Branche","year":"2016","journal-title":"PLoS One"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/12\/ofy327\/33578151\/ofy327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/12\/ofy327\/33578151\/ofy327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:32:17Z","timestamp":1597048337000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy327\/5227985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy327","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,12,1]]},"article-number":"ofy327"}}